<DOC>
	<DOCNO>NCT00478660</DOCNO>
	<brief_summary>Due rigor clinical development program adalimumab indication AS , population subject active AS could enroll previous phase 3 study limit . Therefore , necessary evaluate use adalimumab set mimic day-to-day clinical practice obtain safety efficacy data allow subject meet characteristic note enter study : - Subjects fail another TNF inhibitor ( etanercept , infliximab ) - Subjects advance spinal ankylosis - Subjects AS associated disorder ( i.e. , uveitis , IBD , psoriasis )</brief_summary>
	<brief_title>An Open-Label Study Evaluate Response Adalimumab Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy TNF-Alpha Inhibitors ( RHAPSODY )</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Able willing give write informed consent comply requirement study protocol Males females 18 year age old Diagnosis AS accord modify New York Criteria Ankylosing Spondylitis 1984.24 Documented active AS base opinion physician least 3 month Active AS BASDAI &gt; = 4 Screening Visit Unsatisfactory response standard AS therapy accordance current national guideline treatment AS TNF inhibitor ( applicable ) include minimum failing least one NSAID . National guideline ( applicable ) must follow guideline strict regard use TNF inhibitor treatment AS Use reliable method contraception , e.g. , IUDs , condom , hormone ( oral , implantable , injectable ) contraceptives female subject childbearing potential . Subject must follow manufacture 's recommendation contraception prior administration study drug 150 day follow last administration adalimumab Able willing selfadminister sc injection available suitable person administer sc injection A negative pregnancy test ( serum HCG ) woman childbearing potential prior start study treatment Subject must evaluate active latent TB infection use PPD skin test , T SPOTTB test , chest xray detail review subject 's medical history . Guidelines regard treatment latent TB must follow prior administration adalimumab Prior treatment investigational agent within 30 day , five halflives product , ever longer Treatment within last six week infliximab within last three week etanercept previous treatment time adalimumab Known allergy excipients adalimumab formulation History current acute inflammatory joint disease origin AS , e.g. , rheumatoid arthritis , psoriatic arthritis , systemic lupus erythematosus etc Treatment corticosteroid ( prednisolone equivalent ) follow condition : Dose &gt; 10 mg/d systemically within 28 day screen Intraarticular injection infiltration peripheral joint tendon within 28 day screen Intraarticular injection sacroiliac joint without therapeutic response &lt; =14 day screen Other medical condition : uncontrolled diabetes , unstable ischemic heart disease , congestive heart failure ( NYHA IIIIV ) , recent stroke ( within three month ) , chronic leg ulcer condition ( e.g. , indwell urinary catheter ) , opinion investigator , would put subject risk participation study History cancer malignant lymphoproliferative disease successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma and/or localize carcinoma situ cervix History positive serology hepatitis B indicate active infection history positive serology hepatitis C History positive HIV status Persistent recurrent infection severe infection require hospitalization treatment iv antibiotic within 30 day , oral antibiotic within 14 day prior enrollment Previous diagnosis sign highly indicative central nervous system demyelinate disease ( e.g. , optic neuritis , ataxia , apraxia ) History active tuberculosis , histoplasmosis listeriosis Female subject pregnant breastfeed History clinically significant drug alcohol abuse last year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>